Pharmaceuticals company Lincoln Pharmaceuticals announced Q1FY26 results Total Income: Rs 169.34 crore compared to Rs 157.69 crore during Q1FY25, change 7.39%. EBITDA: Rs 39.08 crore compared to Rs 33.14 crore during Q1FY25, change 17.92%. PBT: Rs 35.39 crore compared to Rs 29.48 crore during Q1FY25, change 20.05%. PAT: Rs 27.70 crore compared to Rs 23.69 crore during Q1FY25, change 16.93%. EPS: Rs 13.82 for Q1FY26. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said: Many countries had been added for the Cephalosporin plant products and product registration will be offered from these countries. During the Q1FY26 company had started Bulk Drug Manufacturing Plant. For which product approval had been received for 10 products and others are under process. At present company had plant to invest Rs 4 crore for this plant from internal accruals of the company. The company's growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company's liquidity remains solid. Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2-3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion. Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; IS0-900I:2015, IS0-1400I:2015 and IS0-4500 I :20 18. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development. Result PDF